2 results about "Tnfα inhibitors" patented technology

This application provides a method for treating cancer in an individual, the method comprising administering a myeloid cell activator or myeloid cell activation therapy (such as a TLR agonist or STING agonist) and a TNFα inhibitor to the individual. In some cases, the method further comprises administering an SHP-1 inhibitor and / or a tyrosine kinase inhibitor to the individual, and optionally further comprising administering a lymphocyte activator, such as a cytokine (such as IL-2) and / or an immune checkpoint inhibitor (such as anti-PD-1).

The present disclosure provides methods of treating disease (e.g., digestive diseases) by administering an antibody or an antigen portion thereof that binds to sLeA and a TNFα inhibitor, as well as pharmaceutical compositions related thereto.